HEB - Hemispherx Biopharma, Inc.

NYSE American - Nasdaq Real Time Price. Currency in USD

Hemispherx Biopharma, Inc.

860 North Orange Avenue
Suite B
Orlando, FL 32801
United States

Full Time Employees25

Key Executives

NameTitlePayExercisedYear Born
Mr. Thomas K. EquelsExec. Vice Chairman, CEO & PresN/AN/A1953
Mr. Adam PascaleCFO & Chief Accounting Officer282.88kN/A1948
Mr. Peter W. Rodino III, J.D.Exec. Director of Gov.al Relations, Gen. Counsel & Sec.381.16kN/A1951
Mr. Wayne S. SpringateSr. VP of OperationsN/AN/A1971
Dr. David R. StrayerChief Scientific Officer & Medical DirectorN/AN/A1946
Amounts are as of December 31, 2017 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Hemispherx Biopharma, Inc., a specialty pharmaceutical company, engages in the clinical development of drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders in the United States. The company's products include Alferon N Injection, an injectable formulation of natural alpha interferon to treat a category of genital warts, a sexually transmitted disease; and Ampligen for the treatment of chronic fatigue syndrome (CFS). It is also developing Ampligen for the treatment of CFS, Hepatitis B, HIV, and cancer patients with renal cell carcinoma and malignant melanoma. The company was founded in 1990 and is headquartered in Orlando, Florida.

Corporate Governance

Hemispherx Biopharma, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.